The critical role of IgE antibodies in the development of allergic disorders, such as chronic urticaria and AD, is supported by the effectiveness of anti-IgE antibodies, such as omalizumab (Xolair®), in a number of clinical studies [13,14]. This evidence concerns the gene IGHE and Alzheimer disease.